Bulletin from the annual general meeting in Peptonic Medical AB (publ)
The annual general meeting in Peptonic Medical AB (publ) (the "Company") was held today, 24 June 2026, at Eversheds Sutherland Advokatbyrå's premises at Sveavägen 20 in Stockholm. The following main resolutions were passed with the required majority at the meeting.
Adoption of the income statement and balance sheet
The meeting adopted the income statement and balance sheet as included in the annual report for 2025.
Allocation of results
The meeting resolved that the Company's results shall be allocated in accordance with the board's proposal in the annual report. No dividend will be paid for the financial year 2025.
Discharge from liability
Each of the board members and the CEO were discharged from liability for the 2025 administration in accordance with the auditor's recommendation.
Determination of the number of board members and deputy board members
The meeting resolved that the board of directors shall consist of four (4) members without deputies.
Remuneration to the board of directors and auditor
The meeting resolved that remuneration of SEK 200,000 shall be paid to each of the ordinary members and SEK 250,000 to the chairman of the board.
It was further resolved that the auditor's fee shall be paid in accordance with approved invoices in accordance with customary billing standards.
Election of board of directors and auditor
It was resolved to re-elect Daniel Rudeklint, Anders Blom and Tarek Schoeb as board members. Carina Lindqvist was elected as a new member of the board. Anders Blom was re-elected as chairman of the board.
The company's auditor KPMG AB was re-elected as auditor with Dan Beitner as auditor-in-charge.
Authorisation for the board of directors to resolve on new issues of shares, warrants and/or convertibles
It was resolved to authorise the board of directors, during the period until the next annual General Meeting, to decide on the issue of new shares, warrants and/or convertible bonds. If the Board of Directors exercises the authorisation, it may also be done with deviation from the shareholders' preferential rights and/or with provisions on non-cash payment or set-off.
Issues pursuant to this authorization shall be made on market terms. The board of directors shall have the right to determine the other terms and conditions for issues pursuant to this authorization and who shall be entitled to subscribe for the securities issued. The reason why the board of directors shall be able to decide on issues in deviation from the shareholders' preferential rights and/or with provisions regarding non-cash consideration or set-off is to enable the Company to raise capital for the Company, implement strategically motivated collaborations or company acquisitions, and facilitate the implementation of issues for the purpose of strengthening the Company's financial position.
For further information, please contact:
Daniel Rudeklint, interim CEO Peptonic Medical AB
Email: daniel.rudeklint@peptonicmedical.se
Phone: +46 73 158 02 73